Trial Profile

A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With Dementia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmedetomidine (Primary)
Indications Agitation
Focus Adverse reactions; Therapeutic Use
Acronyms TRANQUILITY; TRANQUILITY I
Sponsors BioXcel Therapeutics

Most Recent Events

21 May 2024 According to a BioXcel Therapeutics media release, results from this trial will be presented at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
15 Sep 2022 Status changed from recruiting to completed.
10 Aug 2021 According to a BioXcel Therapeutics media release , topline data from the 40 mcg of this phase 2 trial of BXCL501 expected during Q4 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com